Teledyne agreed to acquire Varex Imaging in a deal valued at about $1.1 billion, extending Teledyne’s push deeper into medical imaging. The move reflects continued consolidation across imaging-adjacent platforms as diagnostics and imaging remain core demand drivers. Innate Pharma secured a large partnership with Sobi for lacutamab in cutaneous T-cell lymphoma, with Sobi paying $75 million upfront and additional milestones tied to development progress and global rights. The agreement sets up TELLOMAK-3, a Phase III trial designed to support accelerated approval in Sézary syndrome. On the licensing front, Gilead exercised an option to obtain an exclusive license for a preclinical bispecific program from Macrogenics, triggering a $10 million payment. The step adds another candidate into Gilead’s pipeline for solid tumors built around novel molecular engagements.